| The prescriber or health should instruct patients, their families, and caregivers to read the Medication Guide should assist them in understanding its contents. Hyponatremia Cases of hyponatremia (some with serum sodium lower than 110 mmol/L) have been reported and appeared to be reversible when was . | The majority of these occurrences have been in elderly individuals, some in patients taking or who were otherwise volume depleted. The average risk of such events in patients receiving antidepressants was 4%, the placebo risk of 2Based on the half-life of Cymbalta, at least 5 days should be allowed after stopping Cymbalta before starting an MAOI? | Following abrupt discontinuation in placebo-controlled clinical trials of up to 10-weeks duration, the following symptoms occurred at a rate than or equal to 2% and at a significantly higher rate in either the MDD or GAD Cymbalta-treated patients compared to those discontinuing from placebo: dizziness ; ; headache ; paresthesia ; vomiting; irritability; and nightmare. Cymbalta be prescribed with care in patients with a history of a seizure disorder. | Physician Directory Find a specialist near . | As with antidepressants, Cymbalta has been associated with cases of clinically significant hyponatremia (seeHyponatremia, under PRECAUTIONS ). | Discontinuation of Treatment with Cymbalta Discontinuation have been systematically evaluated in patients taking Cymbalta. | Whether any of the symptoms described above represent such a conversion is unknown. | |
| There is no information on the effect that alterations in gastric motility may have on the stability of Cymbalta’s enteric coating. | Monoamine Oxidase Inhibitors (MAOI) In patients receiving a serotonin reuptake inhibitor in combination with a monoamine oxidase inhibitor , there have been reports of serious, sometimes fatal, reactions including hyperthermia , rigidity, myoclonus , autonomic instability with possible rapid fluctuations of vital signs, and mental status changes include extreme agitation progressing to delirium and coma. | The effects of combined use of Cymbalta and MAOIs not been evaluated in humans or animals. | Some cases presented with features resembling neuroleptic malignant syndrome. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any during duloxetine treatment, particularly after dose increases. | Based on the half-life of Cymbalta, at least 5 days should be allowed after stopping Cymbalta before starting an MAOI? | |
| Postmarketing reports have described cases of hepatitis with abdominal pain , hepatomegaly and elevation of levels to more than twenty times the upper limit of normal or without jaundice , reflecting a mixed or hepatocellular pattern of liver injury. | Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time during duloxetine treatment, particularly after dose increases. | |